MSC-derived Exosomes
Bronchopulmonary Dysplasia (BPD) in preterm babies
Phase 1Active
Key Facts
Indication
Bronchopulmonary Dysplasia (BPD) in preterm babies
Phase
Phase 1
Status
Active
Company
About EXO Biologics
EXO Biologics is a clinical-stage biotech pioneering the development of exosome-based therapeutics and a scalable manufacturing platform. The company employs a triple-axis strategy targeting rare inflammatory diseases, developing a proprietary drug loading technology, and operating a GMP production site to supply high-quality exosomes for internal and external use. It has achieved significant milestones, including initiating the first EMA-approved clinical trial for MSC-derived exosomes and securing substantial Series A funding to advance its pipeline and platform.
View full company profile